5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis.
5-Aminosalicylic acid
Colitis, ulcerative
Dysbiosis
Prognosis
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
14
07
2019
accepted:
06
11
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota. We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC. Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05). In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota.
METHODS
METHODS
We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC.
RESULTS
RESULTS
Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05).
CONCLUSIONS
CONCLUSIONS
In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC.
Identifiants
pubmed: 32013315
pii: ir.2019.00084
doi: 10.5217/ir.2019.00084
pmc: PMC7000647
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-78Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 16gm1010003h0001
Références
Am J Gastroenterol. 2012 Oct;107(10):1452-9
pubmed: 23034604
Scand J Gastroenterol. 2015 Apr;50(4):399-405
pubmed: 25633468
Am J Gastroenterol. 2012 Dec;107(12):1879-87
pubmed: 23165448
PLoS One. 2017 Oct 3;12(10):e0185500
pubmed: 28973005
Inflamm Bowel Dis. 2017 Oct;23(10):1702-1709
pubmed: 28906291
Ann Allergy Asthma Immunol. 2017 Apr;118(4):518-520
pubmed: 28284977
Aliment Pharmacol Ther. 2018 Jan;47(1):26-42
pubmed: 29034981
Gut. 2014 Aug;63(8):1275-83
pubmed: 24021287
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Am J Gastroenterol. 2014 May;109(5):705-14
pubmed: 24642581
Gut. 2018 Dec;67(12):2107-2115
pubmed: 29980607
Am J Gastroenterol. 2011 Apr;106(4):601-16
pubmed: 21407188
PLoS One. 2014 Apr 07;9(4):e94208
pubmed: 24710620
Gastroenterology. 2017 May;152(7):1671-1678
pubmed: 28192102
Am J Gastroenterol. 2005 Jun;100(6):1345-53
pubmed: 15929768
Digestion. 2017;96(1):29-38
pubmed: 28628918
Am J Gastroenterol. 2018 Aug;113(8):1125-1136
pubmed: 29915396
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
Hepatology. 2017 Dec;66(6):1727-1738
pubmed: 28586116
Science. 1995 Nov 17;270(5239):1203-7
pubmed: 7502046
Aliment Pharmacol Ther. 2017 May;45(9):1179-1192
pubmed: 28261835
Front Immunol. 2017 Aug 14;8:942
pubmed: 28855901
BMC Gastroenterol. 2010 Nov 12;10:134
pubmed: 21073731
Diabetes. 2017 Aug;66(8):2137-2143
pubmed: 28446519
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):17-24
pubmed: 29100842
Clin Psychopharmacol Neurosci. 2016 Aug 31;14(3):231-7
pubmed: 27489376
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
N Engl J Med. 2011 Nov 3;365(18):1713-25
pubmed: 22047562
Gut. 2019 Jun;68(6):977-984
pubmed: 30420398
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
BMC Microbiol. 2017 May 22;17(1):120
pubmed: 28532414
Cochrane Database Syst Rev. 2016 May 09;(5):CD000544
pubmed: 27158764
J Crohns Colitis. 2010 Feb;4(1):28-62
pubmed: 21122489
Aliment Pharmacol Ther. 2017 Aug;46(4):389-400
pubmed: 28653751
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
pubmed: 16033867
Nature. 2012 Aug 9;488(7410):178-84
pubmed: 22797518
Dig Liver Dis. 2001 Oct;33(7):563-9
pubmed: 11816545
Inflamm Intest Dis. 2017 Nov;2(2):116-123
pubmed: 30018962
Cell. 2016 Nov 17;167(5):1339-1353.e21
pubmed: 27863247
Gut. 2002 Oct;51(4):536-9
pubmed: 12235076
Pediatr Int. 2017 May;59(5):583-587
pubmed: 28063246
DNA Res. 2016 Apr;23(2):125-33
pubmed: 26951067
Am J Gastroenterol. 1992 Aug;87(8):1029-32
pubmed: 1353658
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224
pubmed: 28612983
Endocrine. 2017 Nov;58(2):207-227
pubmed: 29052181
Am J Gastroenterol. 2018 Jan;113(1):58-71
pubmed: 29206816
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):695-696
pubmed: 28974350
J Affect Disord. 2018 Aug 1;235:506-512
pubmed: 29684865
Aliment Pharmacol Ther. 2018 Jun;47(12):1610-1622
pubmed: 29672874
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091